

MRIdian® PANCREAS Bibliography

FDA-cleared since 2012, ViewRay’s MRIdian is actively being used to treat cancer patients at leading cancer centers worldwide. This bibliography has been prepared by ViewRay to highlight the capabilities of ViewRay’s innovative MRIdian radiation therapy technology.

In this bibliography, we list peer-reviewed publications that have been published by members of the radiation oncology care teams who have pioneered the use of MR image guidance in Radiation Therapy using ViewRay’s MRIdian technology.

MRIdian Clinical Studies	2
OTHER – TUMOR SITES.....	3
MRIdian Technology Description and Evaluation	3
MRIdian Health Economics	4

The materials referenced are for educational and informational purposes only and not for the purpose of providing legal, medical, regulatory, or other professional advice. While an effort is made to post only the most accurate available information, ViewRay does not guarantee that the materials posted, or the information contained therein are the most current. ViewRay does not warrant or make any representations as to the content, accuracy or completeness of the information, text, graphics, links, and other items contained in these materials. The materials referenced are not intended to be a complete presentation of all information or issues for any topic.

MRIdian Clinical Studies

Pancreas

- Bohoudi, O., Bruynzeel, A. M. E., Senan, S., Cuijpers, J. P., Slotman, B. J., Lagerwaard, F. J., et al. (2017). Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. *Radiotherapy and Oncology*, 125(3), 439–444.
- Bohoudi, O., Bruynzeel, A.M.E., Meijerink, M.R., Senan, S., Slotman, B.J., Palacios, M.A., Lagerwaard, F.J. (2019). *Radiotherapy and Oncology*, 132:16-22.
- Bryant, J.M., Palm, R.F., Liveringhouse, C., Boyer, E., Hodul, P., Malafa, M., et al. (2022). Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART). *Advances in Radiation Oncology*, 7(6), 101045.
- Chuong, M.D., Herrera, R., Ucar, A., Aparo, S., De Zarraga, F., Asbun, H., et al. (2022). Causes of death among initially inoperable pancreas cancer patients after induction chemotherapy and ablative 5-fraction stereotactic magnetic resonance image-guided adaptive radiation therapy. *Advances in Radiation Oncology*. Advanced online publication, <https://doi.org/10.1016/j.adro.2022.101084>
- Chuong, M.D., Bryant, J., Mittauer, K.E., Hall, M., Kotecha, R., Alvarez, D., et al. (2020). Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy (MRgRT) with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer. *Practical Radiation Oncology*, 11(2):134-147.
- Chuong, M.D., Herrera, R., Kaiser, A., Rubens, M., Romaguera, T., Alvarez, D., et al. (2022). Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer. *Frontiers in Oncology*. Advanced online publication, <https://doi.org/10.3389/fonc.2022.888462>
- Kim, H, Olsen, J.R., Green, O.L, Chin, R.I., Hawkins, W.G., Fields, R.C., et al. (2022). MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial. *International Journal of Radiation Oncology*Biophysics*Physics*, S0360-3016(22)00735-0.
- Luterstein, E., Cao, M., Lamb, J., Raldow, A. C., Low, D. A., Steinberg, M. L., et al. (2018). Stereotactic MRI-guided adaptive radiation therapy (SMART) for locally advanced pancreatic cancer: a promising approach. *Cureus*, 10(3), e2324.
- Michalet, M., Bordeau, K., Cantaloube, M., Valdenaire, S., Debuire, P. Simeon, S., et al. (2022). Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study. *Frontiers in Oncology*, 12:842402.
- Olberg, S., Green, O., Cai, B., Yang, D., Rodriguez, V., Zhang, H., et al. (2018). Optimization of treatment planning workflow and tumor coverage during daily adaptive magnetic resonance image guided radiation therapy (MR-IGRT) of pancreatic cancer. *Radiation Oncology*, 13(1), 51.
- Pavic, M., Niyazi, M., Wilke, L., Corradini, S., Vornhülz, M., Mansmann, U., et al. (2022). MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic

pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC). *Radiation Oncology*, 17(1):18.

Placidi, L., Romano, A., Chiloiro, G., Cusumano, D., Boldrini, L., Cellini, F., et al. (2020). On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations. *Technical Innovation Patient Support Radiation Oncology*, 15:15-21.

Ramey, S. J., Padgett, K. R., Lamichhane, N., Neboori, H. J., Kwon, D., Mellon, E. A., et al. (2018). Dosimetric analysis of stereotactic body radiation therapy for pancreatic cancer using MR-guided tri-⁶⁰Co unit, MR-guided LINAC, and conventional LINAC-based plans. *Practical Radiation Oncology*, 8(5), e312–e321.

Rudra, S., Jiang, N., Rosenberg, S. A., Olsen, J. R., Roach, M. C., Wan, L., et al. (2019). Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. *Cancer Medicine*, 8(5), 2123–2132.

Simpson, G., Spieler, B., Dogan, N., Portelance, L., Mellon, E.A., Kwon, D., et al. (2020). Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study. *Medical Physics*, 47(8):3682-3690.

Tomaszewski, M.R., Latifi, K., Boyer, E., Palm, R.F., El Naqa, I., Moros, E.G., et al. (2021). Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. *Radiation Oncology*, 16(1):237.

Tyran, M., Jiang, N., Cao, M., Raldow, A., Lamb, J. M., Low, D., et al. (2018). Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy. *Radiotherapy and Oncology*, 129(2), 319–325.

Witt, J.S., Kuczmarska-Haas, A., Lubner, M., Reeder, S.B., Cho, S.Y., Minter, R., et al. (2020). A Phase I Dose Escalation Study of Neoadjuvant SBRT plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. *International Journal of Radiation Oncology*Biography*Physics*, 109(2):458-463.

OTHER – TUMOR SITES

Nierer, L., Eze, C., da Silva Mendes, V., Braun, J., Thum, P., von Bestenbostel, R., et al. (2022). Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate. *Radiation Oncology*, 17(1):53.

Sim, A.J., Hoffe, S.E., Latifi, K., Palm, R.F., Feygelman, V., Leuthold, S., et al. (2022). A Practical Workflow for MR-Guided Stereotactic Body Radiation Therapy to the Pancreas. *Practical Radiation Oncology*, S1879-8500(22)00209-0. doi: 10.1016/j.prro.2022.07.001.

MRIdian Technology Description and Evaluation

van Sornsen de Koste, J. R., Palacios, M. A., Bruynzeel, A. M. E., Slotman, B. J., Senan, S., Lagerwaard, F. J. (2018). MR-guided gated stereotactic radiation therapy delivery for lung, adrenal, and pancreatic tumors: a geometric analysis. *International Journal of Radiation Oncology*Biography*Physics*, 102(4), 858–866.

MRIdian Health Economics

- Palm, R.F., Eicher, K.G., Sim, A.J., Peneguy, S., Rosenberg, S.A., Wasserman, S., Johnstone, P.A.S. (2021). Assessment of MRI-Linac Economics under the RO-APM. *Journal of Clinical Medicine*, 10(20):4706.
- Parikh, N. R., Lee, L., Raman, S., Cao, M., Lamb, J., Tyran, M., et al. (2020). Time-driven activity-based costing comparison of CT-guided versus MR-guided SBRT. *JCO Oncology Practice*, 16(11):e1378-e1385.
- Parikh, N.R., Clark, M.A., Patel, P., Kafka-Peterson, K., Zaide, L., Ma, T.M., et al. (2021). Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT. *Applied Radiation Oncology*, 10(3):33-40.
- Schumacher, L.E.D, Dal Pra, A., Hoffe, S.E., Mellon, E.A. (2020). Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer. *The British Institute of Radiology*, 93(1114):20200028.
- Slotman, B.J., Clark, M.A., Özyar, E., Kim, M., Itami, J., Tallet, A., et al. (2022). Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia. *Radiation Oncology*, 17(1):146.